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Abstract
Introduction: The effect of intra-articular injection of matrix metalloproteinase (MMP)-3 inhibitor was investigated
in a rat model to understand the role of MMP-3 in cartilage degradation induced by excessive loading from
running.
Methods: A total of 24 male Wistar rats were randomly assigned into groups of sedentary control (SED), high-
intensity running (HIR), HIR + low dosage of MMP-3 Inhibitor I (HIRI1), and HIR + high dosage of MMP-3 Inhibitor I
(HIRI2). Rats in the HIR, HIRI1 and HIRI2 groups were intensively trained for six weeks on the treadmill. Those in
HIRI1 and HIRI2 groups were provided bilateral intra-articular injections of 80 μL of 0.2 mM and 2 mM MMP-3
Inhibitor I in knee joints once a week, respectively. Blood samples were collected to measure serum MMP-3 level
using ELISA. Femoral condyles were collected to observe cartilage characteristics by histochemistry, and MMP-3 as
well as collagen II was measured by immunohistochemistry. In addition, cartilage samples were obtained to assess
MMP-3 mRNA expression by RT-PCR.
Results: Histological examination showed osteoarthritic changes in rats after six weeks of high intensity running. In
comparison to the SED group, significant decreases in glycosaminoglycans (GAG) and collagen content were found
in the HIR group, which corresponded to significant increase in serum MMP-3 level, cartilage MMP-3 activity and
gene expression. However, such a degradative process was considerably retarded by intra-articular injection of
MMP-3 inhibitor at higher dosage. Statistical differences were found between the HIR and HIRI2 groups with regard
to GAG and collagen II content, serum MMP-3 level, cartilage MMP-3 activity and gene expression.
Conclusions: High-intensity running for six weeks may lead to cartilage degradation in a rat model. It was shown
that the chrondroprotective effect was offered by the use of intra-articular injection of MMP-3 inhibitor. MMP-3 acts
as the key mediator of this catabolic change under such mechanical condition. The results also showed that MMP-
3 selective inhibitor may be an effective option for retarding such osteoarthritic changes.
Keywords: running exercise, MMP-3, cartilage, osteoarthritis, inhibitor
Introduction
While the homeostasis of joints was stabilized in a phy-
siological range of mechanical loading, non-physiological
mechanical loading and both overloading and reduced
loading, may have deleterious effects, particularly on
their cartilaginous components [1-3]. Running is one of
the most common weight-bearing activities, and moder-
ate running exercise was found to protect against carti-
lage degradation in hamsters that could spontaneously
develop osteoarthritis (OA) [4]. Nevertheless, excessive
running loading was correlated with deleterious effects
on cartilage [5-8], hence, an excessive running-induced
animal model can serve as a reliable OA model [8].
Excessive mechanical stress can directly damage the
cartilage extracellular matrix (ECM) and shift the bal-
ance in chondrocytes to favor catabolic activity over
anabolism [9]. Catabolism of the cartilage ECM was
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defined by the occurrence of degradation of both col-
lagen fibrils and proteoglycans [10]. This involves a vari-
ety of degradative enzymes, notably matrix
metalloproteinases (MMPs), whose basic role is to
cleave and initiate the degradation of cartilage compo-
nents [11]. The MMP family mainly consists of the col-
lagenases (MMPs 1, 8, and 13), which degrade collagen;
the gelatinases (MMPs 2 and 9), which target denatured
collagen; and the stromelysins (MMPs 3, 7, 10, and 11),
which degrade several ECM proteins and are involved in
proenzyme posttranslational activation [12].
In vitro and in vivo studies indicated that a variety of
MMPs may be responsive to diverse loading parameters,
and may promote degradation of the cartilage collagens
and proteoglycan under non-physiological loading con-
ditions [2,7,13-16]. Among the MMPs family, MMP-3
appears to be one of the few genes that is up-regulated
during the early stage of degeneration [17]. In addition,
MMP-3-knockout mice showed a 67% reduction in car-
tilage damage occurring through spontaneous OA [18].
Furthermore, in a rat model, elevated MMP-3 activity
was coincident with osteoarthritic changes in the knee
which were induced by intensive running [7]. Although
it is believed that MMP-3 may be a key mediator in
pathological cartilage matrix degradation, it remains
unclear as to its roles in the pathology of cartilage
degradation, particularly in which was induced by exces-
sive running loading. All in all, in this current study, a
MMP-3 selective inhibitor was administrated to observe
whether it offered a protective effect on cartilage degra-
dation induced by excessive running loading and, subse-
quent to a further understanding of the roles, whether
MMP-3 could have a part in the degradation of cartilage
ECM under such mechanical conditions.
Materials and methods
Experimental animals and study protocol
A total of 24 male Wistar rats (12 to 13 weeks old,
weighing 200 to 250 g) were randomly and evenly
assigned to one of four groups as follows: 1) sedentary
control (SED), 2) high intensity running (HIR), 3) high
intensity running + low dosage of MMP-3 Inhibitor I
(HIRI1), and 4) high intensity running + high dosage of
MMP-3 Inhibitor I (HIRI2). Rats were housed in cages
under controlled light/dark (12/12 h) and temperature
(22 ± 1°C) conditions, and were provided with food and
water ad libitum. They were adapted to laboratory con-
ditions for one week before experiments began. The
experiment was approved by the animal ethics commit-
tee of the institute.
Rats in the HIR, HIRI1 and HIRI2 groups were first
accustomed to exercise for one week, by running on a
treadmill at the speed of 10 m/minutes for 30 min-
utes/day. In the subsequent six weeks, they were
regularly trained for 1 h/day at the frequency of five
days/week, while the speed and inclination of the
treadmill were adjusted to 25 m/minute and 12°, which
were used to elicit high intensity (85% VO2max values)
for Wistar rats [19]. Those rats in the HIRI1 and
HIRI2 groups were provided intra-articular injections
of 80 μL of 0.2 mM and 2 mM MMP-3 Inhibitor I
(Chemical formula C27H46N10O9S, EMD Biosciences,
Inc. San Diego, CA, USA) in knee joints bilaterally
once a week, respectively.
Serum MMP-3 concentration
After six weeks, the blood of all rats was collected prior
to sacrifice and stored at -80°C until assayed. Serum
levels of MMP-3 were measured using commercial
enzyme-linked immunosorbent assay kits (ELISA, R &
D Systems Inc., Minneapolis, MN, USA) according to
the manufacturer ‘s protocol.
Tissue preparation
For histological morphology and immunohistochemistry
examinations, femoral condyles on the right sides of rats
in each group were dissected and fixed in 4% buffered
formaldehyde pH 7.4 for 24 hours. Decalcification was
completed in 10% EDTA solution, and then the samples
were embedded in paraffin wax. Thereafter, they were
cut into 5-mm sagittal sections in the medial region.
For the real-time PCR analysis, articular cartilage sam-
ples from femoral condyles on the left sides were
obtained with a scalpel or rongeur, and flash-frozen in
liquid nitrogen at -80°C.
Histomorphological evaluation
The samples were stained with Safranin-O and histo-
morphologically evaluated with Mankin grading system,
which was previously applied to many experimental OA
models [4-8], and proven to be sensitive to early OA
changes induced by treadmill exercise [8]. The histologi-
cal evaluation system for OA was classified into four
categories: Mankin score of 0, no OA; Mankin scores of
1 to 5, mild OA; scores of 6 to 10, moderate OA, and
scores 11 to 14, severe OA. All sections were graded by
two independent observers that were kept unaware of
the groups.
Digital densitometry was used for the evaluation of the
glycosaminoglycans (GAG) content. For each section, six
different areas were digitally captured with a color video
camera attached to a light microscope. Illumination
intensity and image magnification were kept constant
for all images captured. The information was assessed
with computer image analysis software (Nikon H600L
Microscope and image analysis system, Tokyo, Japan).
The values of optical density in six areas were averaged
to be GAG content in each section.
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Immunohistochemistry for MMP-3 and collagen type II
In addition to histomorphological evaluation, immuno-
histological analysis for MMP-3 and collagen type II was
performed in all sections. After deparaffinization and
rehydration of the tissue sections, MMP-3 and collagen
type II were respectively immunostained with the two-
step immunohistochemistry method instructed by the
manufacturer (Zhongshan Goldenbridge Biotechnology
Co., Ltd, Beijing, China).
The sections were incubated with rabbit polyclonal
antibody against rat MMP-3 (1:50 dilution, Santa Cruz
Biotechnology, Santa Cruz, CA, USA) for 3.5 h at 29°C.
The slides were washed in PBS three times, and fol-
lowed by a 20-minute incubation at 37°C with goat anti-
rabbit anti-MMP-3 immunoglobulin G (IgG) (Santa
Cruz Biotechnology) and visualized with DAB chroma-
gen. The slides were stained for 40 s, and then we coun-
terstained the nucleus with hematoxylin for 6 s.
Negative control sections were prepared with the same
protocol above, but primary antibody was replaced by
PBS. Immunostaining for MMP-3 in the joint cartilage
was evaluated by calculating the ratio of the number of
MMP-3 immunoreactive chondrocytes to the total num-
ber of chondrocytes within each section.
The procedure of staining collagen type II was similar
to the protocol mentioned above with the following
changes: monoclonal mouse antirat collagen type II anti-
body (1:200 dilution, Fisher Scientific, Chicago, IL, USA)
was applied as the primary antibody, and anti-mouse
IgG/HRP (Fisher Scientific) as the secondary antibody.
The collagen type II content was evaluated based on
optical density measured using image analysis software
(Nikon H600L Microscope and image analysis system).
Real-time PCR analysis
The samples were frozen in liquid nitrogen, and then
were broken into pieces with a masher. The fragments
were then mixed and placed in a vessel containing 1 ml
Trizol, then centrifuged at 12,000 rpm for 15 minutes at
4°C. Afterwards, 0.2 mL chloroform was added prior to
mixing, the supernatant was removed after centrifuga-
tion at 12,000 rpm for 15 minutes at 4°C. Then 500 mL
isopropanol was added and the samples were once again
centrifuged at 12,000 rpm for 15 minutes at 4°C. The
supernatant was discarded; 75% ethanol and 500 mL
DEPC-treated H2O were added. The samples were cen-
trifuged at 7,000 rpm for five minutes at 4°C, the super-
natant was discarded, and the pellet was air dried.
Subsequently, 30 mL of DEPC-treated H2O was added.
Reverse transcription of the mRNA to template cDNA
was completed with the transcription RT Kit (TaKaRa
Biotech Co., Ltd., Dalian, China). Two nanograms of
total RNA were analyzed by real-time PCR with SYBR
Green to assess MMP-3 expression, and b-actin as
housekeeper. PCR primers pairs (Bio Teke Co., Ltd.,
Beijing, China) used were: MMP-3, forward 5’-
GGGAAGCTGGACTCGAACACT-3’, reverse 5’-TGAG-
CAGCAACCAGGAATAGG-3’; b-actin, forward 5’-
CCCATCTATGAGGGTTACGC-3’, reverse 5’-
TTTAATGTCACGCACGATTTC-3’. Expression values
of b-actin for each group were averaged and used as a
denominator to determine the relative expression level
of MMP-3.
Statistical analysis
Results are expressed as the mean ± standard deviation.
Statistical analysis was carried out using a one-way
ANOVA and Tukey’s test for post hoc analysis with sig-
nificance set at P < 0.05.
Results
Histological evaluation
The histological appearance of cartilage sections in the
SED group demonstrated the normal structure of Wistar
rat knee cartilage and subchondral bone (Figure 1A). In
contrast, histological changes of surface irregularities,
cell cloning and moderate reduction in the safranin-O
staining were found in the HIR group (Figure 1B). With
the application of MMP-3 inhibitor, the surface became
smooth. However, reduction of the safranin-O staining
was also detected in the HIRI1 and HIRI2 groups (Fig-
ure 1 C, D).
Figure 2 shows the results of GAG content in each
group. GAG content in HIR group (0.010 ± 0.011) was
significantly lower than in the SED group (0.060 ± 0.037).
The GAG content in the HIRI1 group (0.008 ± 0.005)
was similar to that in the HIR group. However, a signifi-
cant increase was found in the HIRI2 group (0.040 ±
0.012), compared to the HIR group, and no statistical dif-
ference was found between the HIRI2 and SED groups.
Mankin’s score in each group is shown in Figure 3.
The score in the HIR group (3.500 ± 1.049) was higher
than in the SED group (0.250 ± 0.500), which suggested
that mild cartilage degradation was induced by six
weeks of high intensity running. However, compared to
the HIR group, Mankin’s scores were lower in the
HIRI1 group (2.667 ± 1.033) and the HIRI2 group
(1.167 ± 0.753), and a statistically significant difference
was found between the HIRI2 and HIR groups. No sta-
tistical difference was found between the SED and
HIRI2 groups.
Serum MMP-3 level
Figure 4 shows the results of serum MMP-3 level in the
four groups. The level in the SED group (11.437 ± 0.920
ng/mL) was significantly lower than in the HIR group
(86.850 ± 33.158 ng/mL). However, the serum MMP-3
level decreased with the treatment of the MMP-3
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inhibitor. Statistical significance was between the HIRI2
group (30.749 ± 40.416 ng/ml) and the HIR group, but
not between the HIRI2 group and SED group.
Immunohistochemistry
Immunostaining revealed detectability for MMP-3 of the
chondrocytes in cartilage sections. Figure 5 shows the
immunohistochemical staining of MMP-3 and the per-
centage of MMP-3 positive chondrocyte in all groups.
In the SED group, 8.35 ± 4.063% of all visible chondro-
cytes showed immunoreactivity to MMP-3, the ratio
rose significantly to 82.53 ± 11.505% in the HIR group.
Nevertheless, the ratios decreased significantly to 17.68
± 13.789% (HIRI1 group) and 5.59 ± 2.977% (HIRI2
Figure 1 Histological photographs of the representative cartilage tissues in four groups with safranin-O staining. Surface regularities
and arranged chondrocytes were found in SED group (A). However, surface irregularities, cell cloning and moderate reduction in the safranin-O
staining were detected in the HIR group (B). Smooth surface, disarranged chondrocytes and reduction in the safranin-O staining were displayed
in HIRI group (C). Compared with the HIRI1 group, lesser reduction in Safranin-O staining was detected in the HIRI2 group (D). scale bar = 50
μm.
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group). There was no statistical difference between the
HIRI2 group and the SED group.
Immunohistological analysis for collagen type II was
performed in all sections, and the content of collagen
type II in each group is shown in Figure 6. The collagen
content in the SED group (0.577 ± 0.123) was signifi-
cantly lower than in the HIR group (0.142 ± 0.093). With
the application of the MMP-3 inhibitor, the collagen type
II content increased slightly in the HIRI1 group (0.186 ±
0.100), and significantly in the HIRI2 group (0.391 ±
0.096). However, the collagen content in HIRI2 group
was still significantly lower than in the SED group.
mRNA gene expression of MMP-3
As shown in Figure 7, a statistically significant increase
of mRNA gene expression of MMP-3 in the HIR group
Figure 2 The results of GAG content in each group. Significantly lower GAG content in the HIR group was found in comparison with that in
the SED group. A significant difference was found between the HIRI2 group and the HIR group. * P < 0.05 compared to SED group; # P < 0.05
compared to HIR group.
Figure 3 Mankin’s score in each group. There was a significant increase in the HIR group compared to the SED group. However, compared
with the HIR group, Mankin’s scores decreased in the HIRI1 group and in the HIRI2 group, and a statistically significant difference was found in
the HIRI2 group. * P < 0.05 compared to the SED group; # P < 0.05 compared to the HIR group.
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(0.697 ± 0.567) was found in comparison to the SED
group (0.030 ± 0.026). A decrease of mRNA expression
of MMP-3 was found after the treatment with MMP-3
inhibitor (0.694 ± 0.243 for the HIRI1 group, and 0.121
± 0.056 for the HIRI2 group); however, only the differ-
ence between the SED and HIRI2 groups was consid-
ered significant.
Discussion
Mechanical loading of articular cartilage is essential to
regulate the metabolic activity of chondrocytes, and is
required for maintaining normal ECM properties. How-
ever, it is generally believed that excessive mechanical
loading contributes to the degeneration of cartilage and
the onset of OA [20]. Rats running 500 m/day in a run-
ning wheel for 12 weeks showed local softening of the
articular cartilage and decreased GAG content [7]. Early
degeneration of cartilage was observed in rats running
1,500 m/day for 10 weeks at a 5° incline on the tread-
mill [8]. In this current study, rats running 1,500 m/day
for six weeks at a 12° incline on the treadmill also
showed early degeneration of cartilage. This indicated
that during high intensity running, excessive running
load was applied on cartilage in the knee joint, which
led to cartilage degradation.
Among the many cellular activities reported to be sub-
ject to mechanical regulation are the expression and
activation of MMPs in vivo and in vitro [21]. It was
reported that chondrocytes respond to a range of
mechanical loading conditions through diverse meta-
bolic responses, including MMPs synthesis [13-15,22].
Various mechanical loading may encourage different
MMPs expression in cartilage chondrocytes [17]. In par-
ticular, Pap et al. described that load-dependent running
increased the immunoreactivity of MMP-3 in a rat
model [7]. In this current study, mild cartilage degrada-
tion was found in rats with high-intensity running exer-
cise for six weeks, which corresponded with a significant
increase of MMP-3 activity and gene expression. To
further confirm the important role of MMP-3 in carti-
lage degradation, intra-articular injection of MMP-3
inhibitor I was administered. Our findings suggested
that the cartilage catabolic change could be retarded by
the use of MMP-3 inhibitor I. The results also demon-
strated that MMP-3 may act as the key mediator of car-
tilage degradation, particularly as the result of excessive
running.
Along with MMP-3 activity and gene expression in
cartilage, the serum MMP-3 level was found to be sig-
nificantly higher in this study following excessive run-
ning for six weeks. In human studies, an elevated
serum MMP-3 level has been observed in subjects with
joint injury [23] and OA [24-26]; serum MMP-3 level
may predict the rate of cartilage loss in an OA joint
[27]. Interestingly, our results indicated that serum
MMP-3 level decreased after intra-articular MMP-3
Figure 4 The results of serum MMP-3 level in all groups. A significantly higher serum MMP-3 level was found in the HIR group than that in
the SED group. However, serum MMP-3 level decreased with the treatment of the MMP-3 inhibitor. Statistical significance was found in the
HIRI2 group compared with the HIR group. * P < 0.05 compared to the SED group; # P < 0.05 compared to the HIR group.
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inhibitor treatment. The findings of the reduction in
MMP-3 gene expression in the current study demon-
strated that intra-articular MMP-3 inhibitor treatment
could prevent the continuous synthesis of MMP-3.
Therefore, the decrease of serum MMP-3 level after
treatment could be the results of the reduction of
MMP-3 molecules synthesized and/or released from
the joint after the treatment. However, as a systemic
Figure 5 Immunohistochemical staining of MMP-3 and the percentage of MMP-3 positive chondrocyte in all groups (A: SED group; B:
HIR group; C: HIRI1group; D: HIRI2 group; E: negative control).* P < 0.05 compared to SED group; # P < 0.05 compared to HIR group.
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OA biomarker, the serum level of MMP-3 reflected
that the changes not only occur in the signal joint, but
also in other joints. This may partially explain the find-
ing in our study that the serum MMP-3 level in the
HIRI2 group was still approximately two-fold higher
than that in the control group.
In this current study, MMP-3 levels, both in serum
and cartilage, increased significantly in rats with high-
Figure 6 Immunohistochemical staining of collagen type II and the content in all groups (A: SED group; B: HIR group; C: HIRI1group;
D: HIRI2 group; E: negative control). * P < 0.05 compared to SED group; # P < 0.05 compared to HIR group.
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intensity running for six weeks, which was mirrored
with the loss of proteoglycan and collagen II. More
importantly, such changes in GAG and collagen II
induced by high intensity running was reversed by
MMP-3 inhibitor treatment, which also implied the
requirement of MMP-3 in regulating proteoglycan and
collagen II homeostasis. It was, therefore, not surprising
that MMP-3 expression corresponded to the appearance
of GAG loss in cartilage following high-intensity run-
ning, and could be suppressed by the MMP-3 inhibitor.
Proteoglycans provide elasticity and lubricity to the joint
surface. Aggrecan degradation is an early sign of ECM
destruction in osteoarthritic cartilage. On the other
hand, type II collagen content was found reduced signif-
icantly followed by high-intensity running, which may
be explained by the fact that MMP-3 contributed indir-
ectly to the breakdown of type II collagen by activating
other MMPs [28]. Collagen fibrils form a meshwork that
provides tensile resistance of the cartilage. Tensile fail-
ure of the collagen meshwork has been proposed as an
important mechanism of failure of articular cartilage
[29].
Our results showed that the degradation of cartilage
ECM was induced by excessive loading from running
in a rat model. In vitro evidence suggested that over-
loading may also lead to chondrocyte death [30,31]. In
human OA cartilage, higher numbers of apoptotic
chondrocytes were found than those in normal carti-
lage, suggesting that apoptosis plays an important role
in the development of OA [32,33]. In a literature
review, Kuht et al. indicated that cell death and extra-
cellular matrix degradation are linked and contribute
to the chronic matrix remodeling process that charac-
terizes OA [34]. As such, it is assumed that the num-
ber of apoptotic chondrocytes may increase following
excessive running loading, which contributes to the
matrix degradation demonstrated in our study. How-
ever, to understand the extent of cell death in this
model, as well as whether the MMP-3 inhibitor pro-
tects against cell death, further investigations using the
TUNEL technique are required.
Due to the important roles in the pathology of carti-
lage matrix degradation, MMPs have long been consid-
ered excellent potential treatment for OA, and
inhibition of their activities has proven to be efficacious
in a variety of models of experimentally induced as well
as spontaneously occurring OA [35-38]. Mainly because
of the musculoskeletal side effects caused by the use of
broad-spectrum MMP inhibitors, current drug develop-
ment strategies for treatment of OA are focused on
inhibition of specific MMPs implicated in the disease
process [39-41]. In this current study, intensity running
would initiate the expression and activation of MMP-3,
leading to catabolism of ECM in cartilage; such degrada-
tion could be retarded by the use of MMP-3 selective
inhibitor at appropriate dosages. As such, intra-articular
injection of MMP-3 inhibitor appears to be an effective
treatment for retarding the cartilage degradative changes
particularly induced by excessive running. However, as
such inhibitive effects were found to be dosage-
Figure 7 MMP-3 gene expression in each group. There was a statistically significant increase in mRNA gene expression of MMP-3 in the HIR
group compared to the SED group. A decrease in mRNA expression of MMP-3 was found after the treatment with MMP-3 inhibitor with a
statistical difference only in the HIRI2 group. * P < 0.05 compared to SED group; # P < 0.05 compared to HIR group.
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dependent in this current study, further investigations
are required for the optimal dosage of MMP-3 inhibitor.
Conclusions
Mild cartilage degradation was observed in rats after
high-intensity running for six weeks, and MMP-3 clearly
acted as the key mediator of this catabolic change under
such mechanical conditions. A chrondroprotective effect
was provided by intra-articular injection of MMP-3 inhi-
bitor, which not only confirmed the important role of
MMP-3 in the changes of articular cartilage induced by
excessive running load, but also suggested a possible
effective treatment for retarding such osteoarthritic
changes.
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